Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels and responses to half of all oxidatively metabolized drugs. CYP3A activity is the sum activity of the family of CYP3A genes, including CYP3A5, which is polymorphically expressed at high levels in a minority of Americans of European descent and Europeans (hereafter collectively referred to as 'Caucasians'). Only people with at least one CYP3A5*1 allele express large amounts of CYP3A5. Our findings show that single-nucleotide polymorphisms (SNPs) in CYP3A5*3 and CYP3A5*6 that cause alternative splicing and protein truncation result in the absence of CYP3A5 from tissues of some people. CYP3A5 was more frequently expressed in livers of African Americans (60%) than in those of Caucasians (33%). Because CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, CYP3A5 may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
Introduction
A major goal of the Human Genome Project has been completed with publication of the draft sequence of the human genome 1, 2 . Understanding the biological and medical implications of variation in the human genome sequence is another major aim of the Human Genome Project 3, 4 . Cytochromes P450 (CYP) are particularly amenable for rapid identification of functionally important sequence variations, because CYP catalytic activities can be determined by various in vivo and in vitro drug bioassays. Moreover, the applications of such information are particularly relevant for pharmacogenomics, in which knowledge of SNPs in CYP genes may lead to individualized drug dosing and improved therapeutics 5 . Here we elucidate whether sequence variations in the promoters of genes encoding enzymes of the CYP3A family contribute to variability in CYP3A metabolism.
The cytochromes P450 evolved to catalyze the metabolism of numerous structurally diverse exogenous and endogenous molecules. Approximately 55 different CYP genes are present in the human genome and are classified into different families and subfamilies on the basis of sequence homology. The CYP families have arisen through a process of gene duplication and gene conversion. Members of the CYP3A subfamily catalyze the oxidative, peroxidative and reductive metabolism of structurally diverse endobiotics, drugs, and protoxic or procarcinogenic molecules 6 . The CYP3A members are the most abundant CYPs in human liver and small intestine 7, 8 . Substantial interindividual differences in CYP3A expression, exceeding 30-fold in some populations 9 , contribute greatly to variation in oral bioavailability and systemic clearance of CYP3A substrates, including HIV protease inhibitors, several calcium channel blockers and some cholesterol-lowering drugs. Variation in CYP3A expression is particularly important for substrates with narrow therapeutic indices, such as cancer chemotherapeutics 10 and the immunosuppressants cyclosporin A and tacrolimus (FK506). Such variation in CYP3A can result in clinically significant differences in drug toxicities (for example, nephrotoxicity) and response (for example, graft survival). Moreover, because CYP3A metabolizes estrogens to 2-hydroxyesterone, 4-hydroxyestrone and 16α-hydroxylated estrogens, all of which have been implicated in estrogen-mediated carcinogenicity 11 , variation in CYP3A may influence the circulating levels of these estrogens and the risk of breast cancer.
Human CYP3A activities reflect the heterogeneous expression of at least three CYP3A family members: CYP3A4, CYP3A5 andarticle CYP3A7. The CYP3A genes are adjacent to each other on chromosome band 7q21, but the genes are differentially regulated 12 . Two CYP3A pseudogenes, CYP3AP1 and CYP3AP2, were recently identified 12 . Functional CYP3A4 is found in most adults, with 10-to 40-fold variation in its expression. CYP3A7 is predominantly expressed in fetal life, and its expression seems to be silenced shortly after birth; however, some people express CYP3A7 mRNA into adulthood 13 . CYP3A4 activity is correlated with CYP3A4 mRNA concentrations, indicating that transcriptional control is the primary mechanism for regulating expression of CYP3A4. CYP3A5 was previously detected in livers and small intestines of some adult Caucasians, but the basis for this 'polymorphic' expression is unknown [14] [15] [16] . Recently, two mutations in what was believed to be the CYP3A5 promoter were found to be associated with polymorphic CYP3A5 expression 17 . Sequencing of the CYP3A locus, however, revealed that these SNPs are actually in the promoter of the pseudogene CYP3AP1 (ref. 12) and, thus, cannot be the basis for polymorphic CYP3A5 expression. The CYP3A4, CYP3A5 and CYP3A7 promoters contain multiple putative transcription-factor-binding sites. In particular, a recently discovered nuclear receptor, PXR/SXR (for pregnane X-receptor/steroid and xenbiotic receptor), that binds to a PXR response element in the CYP3A4 and CYP3A7 promoters is important for regulation of the CYP3A proteins 18, 19 . Therefore, we hypothesized that polymorphisms affecting CYP3A activity are present in DNA regulatory sequences. Through a systematic analysis of genomic DNA from a large number of patients with various drug metabolism phenotypes, and through analysis of DNA from the Coriell DNA Polymorphism Discovery Resource (DPDR; ref.
3), we identified all common variants in the promoter regions of CYP3A4, CYP3A5, CYP3AP1 and CYP3A7, and demonstrated ethnic differences in allele frequencies. By performing quantitative immunoblotting and in vitro kinetic assays of drug metabolism, we evaluated the relationship between these common genetic variants and ethnic-and tissue-specific phenotypic variability. In addition, analysis of human liver CYP3A5 cDNA revealed that only those people with a CYP3A5*1 allele produce high levels of full-length CYP3A5 mRNA and express CYP3A5. Those with the CYP3A5*3 allele have sequence variability in intron 3 that creates a cryptic splice site and results in the generation of CYP3A5 exon 3B; this CYP3A5*3 allele encodes an aberrantly spliced mRNA with a premature stop codon. This finding explains the molecular defect responsible for one of the most common polymorphisms in drug-metabolizing enzymes.
Results
We initially performed SNP analysis of the promoter regions of the CYP3A genes on DNA from the smallest DPDR subset ( Table  1) . The minimum DPDR panel contained five variant alleles with a frequency greater than or equal to 1% in the combined study population. These variant alleles included the CYP3A4*1B allele, in which an A→G variant at nt -288 is present in the nifedipinespecific element of the promoter 20 . We detected the CYP3AP1*1 reference allele (G at nt -44 in the promoter) in 43 people (28 heterozygotes and 15 homozygotes). In an unusual haplotype, hereafter referred to as CYP3A7*1C (Table 1) , an approximately 60-bp stretch (nt -129 to -188) of the CYP3A7 promoter seems to have been replaced with sequence identical to the same region in the CYP3A4 promoter. This replacement indicates the occurrence of a gene conversion event 21 .
The Coriell DPDR panel was designed to represent the genetic diversity of United States residents who have ancestors from Europe, Africa, the Americas and Asia. We found no variants in the DPDR panel that were not also seen in the combined study population, but additional CYP3A alleles found in our larger combined population were not present in the DPDR. Most of these alleles were rare (that is, they were seen in only one or two people). To assess the usefulness of the DPDR panel in predicting SNPs, we calculated the probability that common variants would be missed in a random sampling of our combined population. The chance of missing the polymorphic alleles CYP3A4*1B and CYP3AP1*1 was less than 5%, even if the sample consisted of as few as 10 study subjects from the combined population group. If we were to randomly select a sample of 25 subjects, the probability of missing polymorphic CYP3A7*1C alleles would be 15%, that of missing CYP3A7*1E would be 25%, and that of missing CYP3A7*1D would be greater than 60%. The probability of missing the rare alleles CYP3A4*1C, CYP3A4*1D, CYP3AP1*1B and CYP3AP1*1C would be greater than 60%. Thus the DPDR 8-sample subset was more useful in accurately predicting the identity of CYP3A SNPs than a random sampling of 25 people from the combined population.
As has been previously reported 22 , CYP3A4*1B occurred at a much higher frequency in African Americans (q=0. 35) We determined the association of CYP3A alleles with CYP3A phenotypes. None of the SNPs in the CYP3A5 or CYP3A4 promoters, including the CYP3A4*1B allele, were associated with altered CYP3A activities of people whose phenotypes had been determined in vivo by the erythromycin breath test or nifedipine clearance or in vitro by assays for total midazolam hydroxylase or for basal or rifampin-inducible testosterone 6β-hydroxylase activity. Previous studies have noted the polymorphic expression of CYP3A5 in the liver and intestine of approximately 25% of people studied 14, 16, 24 . Although there is good concordance of CYP3AP1*1 (G at nt -44) with high levels of CYP3A5 in the liver 17 , CYP3AP1*1 cannot be responsible for polymorphic CYP3A5 expression. Because we did not find a CYP3A5 promoter variant that correlated with CYP3A5 expression, we determined whether CYP3AP1*1 was in linkage disequilibrium with another variant in CYP3A5 that might be causal. Because the CYP3AP1 genotype is correlated with CYP3A5 expression 17 , we used mRNAs from Caucasian and African American livers representing the CYP3AP1*1/*1, CYP3AP1*1/*3 and CYP3AP1*3/*3 genotypes to generate and sequence the entire CYP3A5 cDNA. The CYP3A5 mRNA content was greater in people with a CYP3AP1*1 allele than in those people homozygous for CYP3AP1*3. All livers contained the full-length CYP3A5 mRNA transcript encoded by CYP3A5*1 (Fig. 1 ). Many people carrying CYP3AP1*3 also carried CYP3A5*3, which encodes only a small amount of normally spliced CYP3A5 mRNA and a splice variant-1 (SV1) mRNA. SV1 results from a SNP at nt 22,893 (in AC005020), which creates a cryptic consensus splice site and exon 3B, an exon derived from intron-3 sequences of CYP3A5 ( Fig.  1 and Table 2 ). The mutated sequence in intron 3 of CYP3A5*3 has a splice site prediction score of 0.9. Because of the premature termination codon in exon 3B, the SV1 mRNA encodes a protein whose sequence is truncated after amino acid 102. We found a second African Americans and encoded a normal CYP3A5 mRNA and a splice variant mRNA in which exon 7 was deleted. This deletion resulted in a frameshift, causing the encoded protein to be truncated at amino acid 184. Sequence analysis of genomic DNA and cDNA synthesized from the spliced variant mRNA from those individuals skipping exon 7 identified a single sequence variation: a 30597G>A synonymous mutation in exon 7 (nt 711 G>A in the CYP3A5 cDNA). This genotype was concordant with the loss of exon 7. This silent mutation may cause exon 7 skipping by disrupting an exonic splicing enhancer 26 .
To determine the association of the CYP3A5 and CYP3AP alleles with CYP3A5 expression, we measured CYP3A5 protein concentration in liver specimens. We found a greater frequency of CYP3A5 (≥21 pmol/mg protein) in African Americans (11/20; 50%) compared with Caucasians (9/27; 33%). All Caucasians and most African Americans with a CYP3A5 content less than 21 pmol/mg protein were homozygous for the CYP3A5*3 allele with G at nt 22,893 leading to cryptic CYP3A5 mRNA splicing, whereas those with CYP3A5 content ranging from 21 to 202 pmol/mg had at least one CYP3A5*1 allele (A at nt 22,893 with no aberrant CYP3A5 mRNA splicing; Fig. 2a,b) . Among the livers of Caucasians, the CYP3A5 allele frequencies conformed to Hardy-Weinberg equilibrium. There was also complete concordance between the CYP3A5*1 and CYP3AP1*1 genotypes and between CYP3A5*3 and CYP3AP1*3 genotypes in Caucasians. Among African Americans, however, there were several outliers when the CYP3AP1 genotype was used to predict African American CYP3A5 phenotype. Specifically, African American liver 788 had a relatively high level of CYP3A5 (54 pmol/mg protein) that was not predicted by a CYP3AP1*3/*3 genotype, but was explained by the CYP3A5*1/*3 genotype. African American livers 624 and 958.29 had relatively low levels of CY3A5 protein that were not predicted by a CYP3AP1*1/*1 genotype, but were better explained by CYP3A5*1/*6 genotypes because the CYP3A5*6 allele generates an mRNA lacking exon 7. The final outlier (African American liver 50) had only a trace amount of CYP3A5 protein that was not predicted by the CYP3AP1*1/*3 genotype or the CYP3A5*1/*3 genotype. This discrepancy may be due to secondary degradation of CYP3A5 and other proteins following poor tissue preservation, or to a second mutation in the coding region of CYP3A5 that confers instability of the protein (for example, CYP3A5*2; ref. 27) .
We examined the rates of midazolam hydroxylation by the same 47 livers. CYP3A4 and CYP3A5 each produce two metabolites: 1´-hydroxymidazolam (1´-OH MDZ) and 4-hydroxymidazolam (4-OH MDZ). The mean reaction velocities were 2.5-fold (P=0.03) higher for the livers of Caucasians and 2.2-fold (P=0.19) higher for the livers of African Americans with at least one CYP3A5*1 allele, compared with those livers of people who were homozygous for CYP3A5*3 (Fig. 3) . The ratio of 1´-OH MDZ to 4-OH MDZ is dependent on substrate concentration and the type of CYP3A enzyme 28 . At a midazolam concentration of 8 µM, the ratio was 5.5 when we used recombinant CYP3A4 and 16.1 when we used recombinant CYP3A5. Thus, with liver microsomes, the observed product ratio depends on the relative amounts of CYP3A4 and CYP3A5 protein. The average ratio of 1´-OH MDZ to 4-OH MDZ was higher in Caucasian livers with at least one CYP3A5*1 allele (8.1±3.0 for *1/*3 genotype) than in those with two CYP3A5*3 alleles (5.9±1.7 for *3/*3; P=0.09). The 
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Measurement of CYP3A quantity in the same 47 livers showed that CYP3A4 content was not significantly different between Caucasian and African American livers. Within each ethnicity there was no difference in mean CYP3A4 content between livers with or without at least one CYP3A5*1 allele. The amount of total CYP3A in Caucasian and African Americans was approximately threefold higher in those with the CYP3A5*1 allele than in people not carrying this allele (P=0.001 and P=0.01, respectively). Moreover, CYP3A5 protein represented more than 50% of the total CYP3A content in onethird of Caucasian livers and over one-half of African American livers. Thus, CYP3A5 represented a considerably greater proportion of total CYP3A than previously estimated 14 and contributed significantly to CYP3A content and catalytic activity.
Because CYP3A5 is variably expressed in human intestine 16 , we took advantage of a unique cohort of paired samples of small intestine and liver to determine whether the CYP3AP1*1 genotype-phenotype concordance is seen in extrahepatic tissues. All people with large quantities of CYP3A5 in the liver also had relatively high intestinal levels of CYP3A5 and were heterozygous or homozygous for the CYP3A5*1 allele (Fig. 4) . Further, the intestinal midazolam product ratio for people with at least one CYP3A5*1 allele (9.6±2.5 for the AG genotype) differed from that for people with two CYP3A5*3 alleles (6.0±0.3; P=0.06).
The CYP3A4*1B allele was originally proposed to be associated with altered CYP3A4 hepatic activity 20, 29, 30 , but this proposal has been controversial 31, 32 . Because the CYP3A4*1B and CYP3AP1*1 or CYP3A4*1B and CYP3A5*1 alleles can all be present in the same person, we hypothesized that it is ultimately the CYP3A5 genotype that influences the overall functional activity of CYP3A. African Americans frequently carried both CYP3AP1*1 and CYP3A4*1B alleles (Table 3) , and using data from those people homozygous for CYP3A4*1B or CYP3AP1*1, we determined the linkage of the two alleles (data not shown; χ 2 =12.8, P<0.001). The association of the CYP3A5*1 and CYP3A4*1B alleles was not significant in African Americans, but approached statistical significance in Caucasians.
The CYP3A7 promoter contains a set of 7 tightly linked variants that replaced 60 bp of the CYP3A7 promoter with the identical region from the CYP3A4 promoter; thus this replacement altered 3 transcription-factor-binding sites 33 : hepatic nuclear factor-5 (HNF-5), an octamer motif and the PXRE. Although CYP3A7 is generally expressed only during fetal development, CYP3A7 mRNA is detected in a small fraction of adults 13 . We speculated that these nucleotides are important for the increased expression of hepatic CYP3A4 and loss of CYP3A7 expression in most people after birth. We evaluated hepatic CYP3A7 mRNA expression in nine adult livers (five with the variant CYP3A7*1C allele) to determine whether this replacement of CYP3A7 promoter elements by CYP3A4 sequences is related to expression of CYP3A7. The two people with the highest levels of CYP3A7 mRNA carried CYP3A7*1C, and four of five people with CYP3A7*1C alleles expressed CYP3A7 mRNA (data not shown). One person with the CYP3A7*1C allele had no CYP3A7 mRNA, however, and two people lacking CYP3A7*1C had very low but detectable levels of CYP3A7 mRNA. Thus, CYP3A7*1C is associated with CYP3A7 mRNA expression, but is not the sole explanation for CYP3A7 expression in adults.
Discussion
Our findings show that SNPs in CYP3A5 that cause alternative splicing and truncation of CYP3A5 protein provide a molecular explanation for the absence of CYP3A5 protein from some people. The most common cause of the loss of hepatic CYP3A5 The new CYP3A5*6 allele, which was identified in African Americans, contained a 30597G>A mutation in exon 7. This SNP correlates with the deletion of exon 7 from the CYP3A5 mRNA and lower CYP3A5 catalytic activity in three African Americans. CYP3A5 expression was also closely associated with the CYP3AP1*1 genotype 12,17 ; however, the CYP3A5 phenotype was better predicted by CYP3A5 genotype. Comparison of CYP3AP1*1 and CYP3A5*1 genotypes among the DPDR subset revealed only 37.5% linkage; in Mexicans, only 65% linkage; and in Japanese, Southeast Asians, Chinese and Pacific Islanders, 90-95% linkage. Although we detected small amounts of normally spliced CYP3A5 mRNA and resulting protein even in those people homozygous for CYP3A5*3, cryptic splices sites within intron 3 were used preferentially. Thus, only those people with at least one CYP3A5*1 allele polymorphically express high amounts of CYP3A5. These results add to the growing list of splicing alterations that affect the expression of clinically important genes 34 . In addition to determining the basis for polymorphic CYP3A5 expression, we demonstrated that in people with at least one CYP3A5*1 allele, the peak hepatic content of CYP3A5 is much higher than previously thought 24, 35 and is approximately the same as the reported peak level of CYP3A4 (ref. 8) . For most Caucasians and African Americans who carry the CYP3A5*1 allele, we also found that CYP3A5 accounts for at least 50% of the total CYP3A content. Thus, CYP3A5 should contribute substantially to the total metabolic clearance of the many CYP3A substrates. Indeed, we predict that people with the highest clearance and lowest oral bioavailability of CYP3A substrates will be heterozygous or homozygous for CYP3A5*1. These people might be more likely to encounter a lack of efficacy from a standard dose of active parent drug. Moreover, because CYP3A4 and CYP3A5 have varying degrees of catalytic capability and regioselectivity toward some substrates and because CYP3A4 and CYP3A5 are differentially inhibited by some compounds, polymorphic CYP3A5 expression will contribute to differences in metabolite profiles and in susceptibility to inhibitory drug interactions. One can also envision an increased risk of adverse effects from CYP3A5-generated toxic metabolites in people that predominantly express CYP3A5. For instance, the rate of 3α-hydroxylation of aflatoxin B 1 (the inactivation step) by CYP3A5 is approximately 1% of that of CYP3A4, whereas CYP3A5 efficiently catalyzes the 8,9-epoxidation (the activation step) of aflatoxin B 1 (ref. 36 ). Thus, in those for whom CYP3A5 is the dominant hepatic CYP3A, the relative lack of aflatoxin B 1 detoxification compared to activation of this agent might enhance the genotoxicity of aflatoxin 36 . Because polymorphic CYP3A5 is one factor contributing to individual variation in CYP3A-mediated metabolism of drugs 14, 35 , simple DNA-based tests can now be used to determine how individual differences in CYP3A5 contribute to the overall metabolic fate of these CYP3A substrates, to their pharmacodynamic variability and to disease risk.
CYP3A5 is the primary CYP3A family member expressed outside the liver and intestine (for example, kidney, lung and polymorphonuclear leukocytes), indicating that CYP3A5 has an important physiologic function in these tissues. Indeed, CYP3A5 can mediate the metabolism of cortisol to 6β-hydroxycortisol, a physiologic regulator of Na + transport in renal epithelia 37 . Variable and polymorphic renal expression of CYP3A5 (refs. 38,39) may contribute to individual differences in the localized generation of 6β-hydroxycortisol within the nephron and may have an etiologic role in, for example, salt-sensitive hypertension by increasing renal retention of Na + . Thus, CYP3A5 is not just a catalyst of drug detoxification, but, in organs such as the kidney, it may serve an important function in regulating the pool of endogenous paracrine or endocrine factors. Similarly, polymorphic expression of CYP3A5 may contribute to variable metabolism of steroids in the prostate and breast, to differences in the concentrations of circulating steroids and, hence, to risk of disease in these tissues.
Among the Caucasians and African Americans studied here, the CYP3A5*1 genotype was associated with significant levels of CYP3A5 protein in the liver and small intestine, the two main tissues in which CYP3A5 is likely to make the greatest contribution to drug elimination. The polymorphic distribution of the CYP3A5*1 allele indicates that relatively high levels of metabolically active CYP3A5 are expressed by an estimated 30% of Caucasians, 30% of Japanese, 30% of Mexicans, 40% of Chinese and more than 50% of African Americans, Southeast Asians, Pacific Islanders and Southwestern American Indians. The higher prevalence of CYP3A5 expression indicates that these non-Caucasians are more likely to experience higher clearance of drugs principally inactivated by CYP3A; are less 20, 29, 30 . Our finding of the simultaneous occurrence of CYP3A4*1B, CYP3AP1*1 and CYP3A5*1 alleles in some people indicates the need to re-evaluate this association and to determine whether the CYP3A5 genotype and CYP3A5 expression are more closely associated with these disease risks.
Data on the frequencies of SNPs in human genes have been largely gathered from surveys of exons and introns 40, 41 , with little specific attention given to the frequency of SNPs in upstream regulatory regions, particularly those of differentially regulated gene family members. Previous studies have reported a nucleotide diversity of about 1 in 2,000 bp of noncoding DNA (consisting mostly of 5´ and 3´ UTRs and introns) and lower frequencies in coding sequences; the least frequent SNP, with a nucleotide diversity of approximately 1 in 20,000 bp, was a coding SNP that causes a nonconservative amino acid substitution 41 . In Caucasians, the observed nucleotide diversity in the CYP3A4 promoter was 1 in 7,246 bp; in the CYP3AP1 promoter, 1 in 2,577 bp; in the CYP3A5 promoter, 1 in 3,175 bp; and in the CYP3A7 promoter, 1 in 4,444 bp. In African Americans the observed nucleotide diversity in the CYP3A4 promoter was 1 in 1,000 bp; in the CYP3AP1 promoter, 1 in 649 bp; in the CYP3A5 promoter, 1 in 2,841 bp; and in the CYP3A7 promoter, 1 in 1,677 bp. It will be of interest to compare the level of nucleotide diversity within the CYP3A promoters with a much larger diverse survey of human gene promoters.
Traditionally, pharmacogenetics research used the strategy of identifying outliers in drug response, obtaining the DNA from outliers and identifying sequence variation in genes involved in that drug's metabolism. In the postgenomic era, reverse pharmacogenetics approaches are under way in which common polymorphisms are first identified in panels of DNA from anonymous people and then screening for these common sequence variations is carried out in people whose drug metabolism phenotype is known. For genes of pharmacogenetic interest, or for any gene, the fewer the number of DNA samples required to detect these common genetic variants, the more rapidly and cost effectively common variants can be identified. Moreover, these common variants are proposed to significantly contribute to risks of common disease 4 . Our results confirm that the smallest subset of eight DPDR samples was sufficient to identify all common polymorphisms in the CYP3A promoters and in the gene CYP3A5, including two polymorphisms that had a high probability of being missed in a random population sample of 25 people. This result indicates the robust power of this resource for rapid SNP discovery.
Methods
Population samples. We sequenced the CYP3A promoters of 159 people. Eight samples were from the DPDR (Coriell Cell Repositories). We also obtained samples from the following sources: 47 livers (27 Caucasian donors, 20 African American donors) whose midazolam 1´-hydroxylase and 4-hydroxylase activities and CYP3A5 and CYP3A4 protein were characterized (University of Washington, University of Pittsburgh, the Medical College of Virginia and St. Jude Children's Research Hospital); primary human hepatocytes from 8 people whose basal and drug-inducible testosterone 6β-hydroxylase activity had been characterized (University of Pittsburgh); kidneys from 12 people (Indiana University); 29 subjects (representatives of 7 families) whose nifedipine clearance had been determined (University of Newcastle upon Tyne, UK); 5 family members, one of whom was a poor nifedipine metabolizer (University of Michigan); 12 pediatric patients (St. Jude Children's Research Hospital); 14 subjects whose hepatic CYP3A phenotype had been determined by using the erythromycin breath test (University of Michigan); 10 subjects whose intestinal CYP3A4 content had been determined (University of Michigan); hepatocytes from 10 people for whom the drug induction of CYP3A protein had been characterized article
